Results for "Understanding Pharmaceutical Distribution"
HDA Dialogue Explores DE&I Efforts In the Distribution Sector
Discussions surrounding diversity, equity and inclusion (DE&I) are critically important to the healthcare distribution industry as this work ultimately strengthens the industry’s ability to deliver safe, affordable and efficient healthcare to patients across the nation. Earlier this month, HDA hosted a virtual discussion with four industry leaders who are fostering belonging within their organizations.
Building a More Climate Resilient Healthcare Supply Chain
Protecting the health of Americans begins with ensuring the well-being of our planet — and healthcare distributors recognize the industry’s responsibility to drive meaningful action on reducing climate change.
Creating Successful Public Health Partnerships in the Age of COVID-19
The coronavirus pandemic fostered and underscored the benefits of public-private partnerships as healthcare supply chain companies used their expertise and strengths to support the government’s response to an ongoing health crisis. The Milken Institute’s “2021 Partnering for Patients Forum” explored this topic during a panel discussion entitled, “Reimagining Public Health Partnerships: Lessons Learned from the Pandemic.”
Rx Supply Chain Progressing on EPCIS Adoption for DSCSA, Yet Challenges Still Remain
Updated survey data released today by the HDA Research Foundation indicate that healthcare supply chain partners remain in the formative stages of establishing the interoperable transaction data connections required to comply with the Drug Supply Chain Security Act (DSCSA) by November 27, 2023. However, some progress has been made since a previous survey conducted last spring.